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Abstract
Pretreatment D-dimer levels have been reported to predict survival in several types
of malignancies in human patients. The objective of this study was to evaluate the
prognostic value of pretreatment D-dimer level in dogs with intermediate to high-
grade non-Hodgkin lymphoma (NHL). In a prospective, randomized, double-blind
study of F14512 vs etoposide phosphate, we assessed the prognostic value of pre-
treatment plasma D-dimer level in 48 client-owned dogs diagnosed with intermediate
to high-grade NHL. The correlation between pretreatment plasma D-dimer level and
various clinical features, progression-free survival (PFS) and overall survival (OS) was
analysed. The median value of pretreatment plasma D-dimer level was 0.4 μg/mL
(range: 0.1-14.3 μg/mL). High pretreatment plasma D-dimer level (>0.5 μg/mL) was
detected in 44% (21/48) of dogs. High D-dimer levels were not correlated with naive
vs relapsed lymphoma, clinical stage, substage, immunophenotype or treatment
group. D-dimer levels >0.5 μg/mL were significantly associated with inferior median
PFS (54 vs 104 days, P = .011) and OS (93 vs 169 days, P = .003). In the multivariate
analysis, high D-dimer levels remained an independent predictor for worse PFS (HR:
3.21, 95% CI: 1.57-6.56, P = .001) and OS (HR: 3.87, 95% CI: 1.88-7.98; P < .001).
This study suggests that pretreatment plasma D-dimer level can serve as a predictor
of prognosis in dogs with intermediate to high-grade NHL. Further studies are
warranted to confirm these findings.
K E YWORD S
D-dimer, dog, lymphoma, prognostic marker, survival
1 | INTRODUCTION
Non-Hodgkin lymphomas (NHL) are among the most common
haematopoietic cancers in both human and dog populations. Canine
NHL shares many biological and therapeutic similarities with their
human counterpart, including clinical presentation, biological behav-
iour and therapeutic responses.1-3 Many clinical and biological factors
have prognostic value in the duration of remission and survival in dogs
with NHL, including WHO clinical stage,4,5 and substage,4,6,7
immunophenotype,4,8-12 histopathological grade,4,11,13 cyto-
morphological subtype,14,15 anatomical location,16-18 and prior steroid
treatment.11,19 Other potential prognostic markers have been evalu-
ated, such as argyrophilic nucleolar organizing regions (AgNOR
staining),20 Ki-67 antibody staining,21 serum lactate dehydrogenase
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(LDH) activity,22,23 serum C-reactive protein,24,25 and serum thymi-
dine kinase 1 (sTK1) activity26 but the accuracy of these markers
remains controversial. Therefore, it is important to determine simple
and accurate prognostic factors for risk stratification before treatment
initiation.
D-dimer, a stable end-product of fibrin degradation, is a widely
used and highly sensitive global indicator of activated coagulation and
fibrinolysis.27 Elevated levels of D-dimer have been reported to corre-
late with poor prognosis in several types of malignancies in human
patients, including breast,28 colorectal,29,30 lung,31-33 gastric,34,35
gynaecological cancers,36 and diffuse large B-cell lymphoma.37 The
mechanisms underlying the prognostic value of D-dimers in cancer
patients are not fully understood. The tumour cells or the stimulation of
tumour-associated inflammatory cells can activate the clotting cascade
and the activation of coagulation and fibrinolysis and may play an
important role in tumour growth, infiltration, metastasis and angiogene-
sis.38,39 As a compensatory mechanism for fibrin clot formation, fibrino-
lysis is activated, and then D-dimer is produced.40-42 Higher plasma D-
dimer levels have been identified in dogs with malignant neoplasia com-
pared with dogs with benign disease,43 and plasma D-dimer levels have
been reported to be associated with advanced tumour stage44 and
high-grade tumour.45,46 However, the clinical significance of D-dimer
levels in dogs with NHL has rarely been investigated. Therefore, the
objective of this study was to determine the correlation between pre-
treatment plasma D-dimer levels with clinical features and survival in
dogs with spontaneously occurring intermediate to high-grade NHL.
2 | MATERIALS AND METHODS
2.1 | Patient selection
This study was part of a comparative oncology project assessing a
new polyamine-vectorized anticancer drug (F14512) compared with
the parent drug etoposide, in dogs with naturally occurring NHL.47
The study design was prospective, randomized and double-blinded.
The study design and the data analysis were carried out by OCR
(Oncovet-Clinical-Research), Loos, France. The study was conducted
at Oncovet, a private referral centre for small animal oncology, Ville-
neuve d'Ascq, France.
In the present study, client-owned dogs were considered eligible
for inclusion if they (i) had a histologically and/or cytologically con-
firmed diagnosis of intermediate to high-grade NHL; (ii) had measur-
able disease at the time of inclusion (allowing staging and clinical
response assessment); (iii) had no anticancer drugs in the month
before inclusion (including steroids); and (iv) had no significant bio-
chemical abnormalities or blood cytopenia, which would precluded
the use of cytotoxic drugs. The exclusion criteria were: (i) active infec-
tion at the time of inclusion; (ii) a history of venous or arterial throm-
boembolism or anticoagulant treatment within the 3 months prior to
inclusion; and (iii) any known congenital coagulative abnormality.
Written informed consent form was obtained from the owner before
enrolment of each dog.
2.2 | Initial staging
All dogs were staged based on the modified WHO five-stage criteria
for canine lymphoma as previously described.47 Initial staging tests
included a complete blood count, blood smear evaluation, biochemis-
try panel, ionized calcemia, whole-body computed tomography, fine-
needle aspirates (FNA) and biopsies of peripheral lymph nodes, ultra-
sound-guided liver and spleen FNA, urine analysis and bone marrow
aspirates. Bone marrow was considered infiltrated if neoplastic lym-
phoid cells represented ≥3% of all nucleated cells on the basis of bone
marrow cytology.48 The definitive diagnosis was confirmed for each
dog from cytological examination of the lymph node aspirates per-
formed by one board-certified clinical pathologist (C. Fournel-Fleury)
and lymphoma was graded according to the updated Kiel morphologi-
cal classification.49 Immunophenotyping was performed using immu-
nohistochemistry as previously described.50 The cytology results and
immunophenotype were recorded for all dogs.
2.3 | Measurement of pretreatment plasma D-
dimer levels
Fasting venous blood samples were collected before treatment initia-
tion. Plasma D-dimer concentrations were measured using a tur-
bidometric immunoassay (Nyco Card Reader II, NYCOMED) according
to the manufacturer's instructions. The D-dimer reference range of
0.1 to 0.5 μg/mL was used based on published data in clinically
healthy dogs.51
2.4 | Measurement of pretreatment sTK1 activity
(DiviTum assay)
Serum samples were collected for sTK1 activity measurement prior to
treatment initiation. Analysis of sTK1 activity was determined by a
refined ELISA assay, the DiviTum assay (lab Biovica International,
Uppsala, Sweden), according to the manufacturer's instructions
(http://biovica.com/), as previously described in dogs.52 The absor-
bance readings to DiviTum units per litre (Du/L) were converted using
the values from standards with known TK activity, with a minimum
detectable activity for this assay of 20 Du/L. The analysis was per-
formed at the Biovica laboratory in Uppsala, Sweden.
2.5 | Treatment modality and follow-up
The treatment protocol used in this study has been previously
described.47 The same induction chemotherapy protocol was followed
in all dogs over a period of 8 weeks. Dogs were randomly assigned to
receive F14512 (0.075 mg/kg), or etoposide phosphate (100 mg/m2),
delivered over a 3-hour intravenous (IV) infusion once daily for three
consecutive days, every 2 weeks for 4 cycles (ie, days 1-3, days 15-
17, days 29-31, days 43-45). The maximum tolerated dose of F14512
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and etoposide phosphate was previously evaluated using two inde-
pendent traditional 3 + 3 phase I dose-escalation trials.50,53
The response to treatment was evaluated before each chemo-
therapy administration. The best response to treatment was deter-
mined based on physical examination and peripheral lymph node size
measurement using a calliper, according to the VCOG Response Eval-
uation Criteria for Peripheral Nodal Lymphoma in dogs version 1.0.54
At the end of 4 cycles (day 62), dogs underwent a complete end-
staging.
After completion of the 4 cycles, dogs who experienced a clinical
benefit (complete or partial response or stable disease) received three
additional consolidation cycles with one IV injection of the same drug
on a 3-week cycle (day 68, 89 and 110). Clinical follow-up was contin-
ued every 4 weeks from completion of treatment until disease pro-
gression, death or withdrawal from the study as a result of the
owner's decision. In cases of disease progression or withdrawal, dogs
were excluded and a doxorubicin-based chemotherapy protocol was
offered to the dog's owner.
2.6 | Statistical analysis
The primary endpoints of the study were progression-free survival
(PFS) and overall survival (OS). PFS was measured from randomization
to any of the following events, whichever occurred first: progression,
relapse, death (related to the lymphoma or not) and evaluated
according to the VCOG criteria v1.0.54 The OS was defined as the
time from randomization to death from any cause, or to the time of
the last follow-up assessment for dogs who remained alive. The sur-
vival data was calculated using the Kaplan-Meier method and com-
pared using a log-rank test. Categorical variables were expressed as
numbers and percentages, and groups were compared with the chi-
square test or, for small numbers, Fisher exact test. Data was tested
for normal distribution using Shapiro-Wilk test for normality. For con-
tinuous, normally distributed variables, data was expressed as mean
and SD, and groups were compared with t-test or analysis of variance
as appropriate. Non-normally distributed continuous variables were
expressed as median and range, and groups were compared using
Wilcoxon rank test or Krustal-Wallis test as appropriate. Evaluation of
correlation between pretreatment plasma D-dimer levels and pre-
treatment sTK1 activity was performed using a Spearman correlation
coefficient. The Cox proportional hazard model was used for a univar-
iate screen of all potential predictors of survival. A univariate analysis
was performed using the following six parameters: prior chemother-
apy, WHO clinical stage, WHO clinical substage, immunophenotype,
treatment group and pretreatment plasma D-dimer level. The P values
of the six outcome univariate tests were corrected for multiple com-
parisons with false discovery rate (FDR) correction by the Benjamini &
Hochberg method.55 The variables with statistical significance were
included in the multivariate analysis using a stepwise forward Cox
regression model. Results were considered statistically significant with
a P value <.05. All statistical analysis was performed with SPSS version
24.0 software (SPSS A, Inc., Chicago, Illinois).
2.7 | Cell line validation statement
No cell line validation testing has been conducted.
3 | RESULTS
3.1 | Epidemiological and clinical characteristics
Forty-eight dogs with naturally occurring intermediate to high-grade
NHL were included in the randomized double-blind study between
December 3, 2014 and August 30, 2016. All 48 dogs met the inclusion
criteria and were analysed. Forty-one (85%) dogs had no prior treat-
ment, and seven (15%) dogs were enrolled after relapse following a
CHOP-based chemotherapy protocol. Twenty-five (52%) dogs were
randomized to receive F14512 and 23 (48%) dogs to receive
etoposide phosphate. The last day of follow-up was January 30, 2017.
The main clinical characteristics are summarized in Table 1.
TABLE 1 Clinical characteristics of dogs with intermediate to
high-grade non-Hodgkin lymphoma (n = 48)
Clinical characteristics Dogs
Number of dogs (%) 48 (100%)
Sex, no. (%)
Male 27 (56%)
Female 21 (44%)
Age, years, mean ± SD (range) 7.5 ± 2.7 (3-14)
Body weight, kg, mean ± SD (range) 28.5 ± 11.7 (8.0-51.4)
WHO clinical stage, no. (%)
Stage II 2 (4%)
Stage III 8 (17%)
Stage IV 29 (60%)
Stage V 9 (19%)
WHO clinical substage, no. (%)
Substage a 26 (54%)
Substage b 22 (46%)
Immunophenotype, no. (%)
B-cell lymphoma 37 (77%)
T-cell lymphoma 7 (15%)
Unclassified 4 (8%)
Prior treatment, no. (%)
Untreated 41 (85%)
Prior chemotherapy 7 (15%)
Treatment group, no. (%)
F14512 25 (52%)
Etoposide phosphate 23 (48%)
Abbreviation: WHO, World Health Organization.
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3.2 | Pretreatment plasma D-dimer level
For the entire cohort, the median value of pretreatment plasma D-
dimer level was 0.4 μg/mL (range: 0.1-14.3). Twenty-seven (56%)
dogs presented with a pretreatment plasma D-dimer level within the
normal range (≤0.5 μg/mL), and 21 (44%) dogs had a pretreatment
plasma D-dimer level above 0.5 μg/mL.
3.3 | Pretreatment plasma D-dimer level and
clinical characteristics
Baseline clinical characteristics of the cohort are presented and com-
pared between dogs with a low (≤0.5 μg/mL) or high (>0.5 μg/mL)
pretreatment plasma D-dimer level in Table 2. There was no correla-
tion between high pretreatment D-dimer level and clinical characteris-
tics including sex, age, body weight, WHO clinical stage and substage,
immunophenotype and prior chemotherapy received before inclusion.
Treatment modalities were balanced between dogs with a low
(≤0.5 μg/mL) or high (>0.5 μg/mL) pretreatment plasma D-dimer
level (P = .99).
3.4 | Correlation between pretreatment plasma D-
dimer level and pretreatment sTK1 activity level
Pretreatment sTK1 activity was measured in all dogs. The median
sTK1 activity was 1374 Du/L (range: 20-60 005 Du/L). A low
TABLE 2 The clinical characteristics and outcome of dogs with low (≤0.5 μg/mL, n = 27) or high (>0.5 μg/mL, n = 21) pretreatment plasma D-
dimer levels
Parameters
Number of dogs (%) with
D-dimer ≤ 0.5 μg/mL
Number of dogs (%) with
D-dimer > 0.5 μg/mL P value
Overall, no. (%) 27 (100%) 21 (100%)
Sex, no. (%) 0.25a
Male 13 (48%) 14 (67%)
Female 14 (52%) 7 (33%)
Age, years, median (range) 7 (3–13) 7 (4-14) 0.40b
Body weight, kg, mean ± SD (range) 26.8 ± 10.4 (11.4-51.4) 30.8 ± 13.1 (8-50) 0.26c
WHO clinical stage, no. (%) 0.15a
Stage II + III + IV 24 (89%) 15 (71%)
Stage V 3 (11%) 6 (29%)
WHO clinical substage, no. (%) 0.24a
Substage a 17 (63%) 9 (43%)
Substage b 10 (37%) 12 (57%)
Immunophenotype, no. (%) 0.44a
B-cell lymphoma 22 (81%) 15 (71%)
T-cell lymphoma 3 (11%) 4 (19%)
Prior chemotherapy, no. (%) 0.11a
Untreated 21 (78%) 20 (95%)
Prior chemotherapy 6 (22%) 1 (5%)
Treatment group, no. (%) 0.99a
F14512 14 (52%) 11 (52%)
Etoposide phosphate 13 (48%) 10 (48%)
Outcome
ORR, no. (%) 21 (78%) 17 (81%) 0.99a
PFS, days (range) 104 (10–224) 54 (4-153) 0.011d
OS, days (range) 169 (10–466) 93 (4-280) 0.003d
Abbreviations: ORR, overall response rate (defined as complete response plus partial response); OS, overall survival; PFS, progression-free survival; WHO,
World Health Organization.
aFisher exact test.
bWilcoxon test.
cT test.
dLog-rank test.
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correlation was observed between pretreatment plasma D-dimer level
and pretreatment sTK1 activity (Spearman correlation rs = 0.38, 95%
CI: 0.10-0.61, P = .007). Serum TK1 activity was not correlated with
PFS (P = .16) or OS (P = .20); Supporting Information Figure S2.
3.5 | Pretreatment plasma D-dimer level and
outcome
Thirty-eight (79%) dogs achieved an objective response with 21 com-
plete response (CR) and 17 partial response (PR). No significant differ-
ence in response rate was observed between dogs with a
pretreatment D-dimer level >0.5 μg/mL and dogs with a D-dimer
level ≤ 0.5 μg/mL (81% vs 78%, P = .99). Twenty-three (48%) dogs
received a doxorubicin-based chemotherapy protocol at the time of
relapse, including 14 dogs with pretreatment D-dimer level ≤ 0.5 μg/
mL and nine dogs with pretreatment D-dimer level > 0.5 μg/mL.
All dogs died from lymphoma or were euthanized because of poor
quality of life secondary to disease progression. For the entire cohort,
the median PFS was 86 days (range: 4-224 days) and the median OS
was 121 days (range: 4-466 days). The median PFS for dogs with a
pretreatment D-dimer level > 0.5 μg/mL was 54 days (range: 4-
153 days) compared with 104 days (range: 10-224 days) for dogs with
a D-dimer level ≤ 0.5 μg/mL (P = .011). For dogs with a pretreatment
D-dimer level > 0.5 μg/mL, the median OS was 93 days (range: 4-
280 days) compared with 169 days (range: 10-466 days) for dogs with
a D-dimer level ≤ 0.5 μg/mL (P = .003). Kaplan-Meier curves are
shown in Figure 1.
In the univariate analysis, dogs with pretreatment D-dimer
level > 0.5 μg/mL were significantly more likely to have a shorter PFS
compared with dogs with pretreatment D-dimer level ≤ 0.5 μg/mL
(HR: 2.22, 95% CI: 1.18-4.19; P = .042, Table 3). Other parameter that
predicted significantly shorter PFS in the univariate analysis included
prior chemotherapy (P = .042). After post hoc correction, WHO stage
V was not found to be significant (P = .066). In the multivariate Cox
regression model, pretreatment D-dimer level > 0.5 μg/mL (HR: 3.21,
95% CI: 1.57-6.56, P = .001) and prior chemotherapy (HR: 5.06, 95%
CI: 1.92-13.37, P = .001) remained independent predictors for worse
PFS .
Univariate and multivariate analyses were also performed for OS
(Table 4). The univariate analysis revealed that pretreatment plasma
D-dimer level > 0.5 μg/mL (P = .024), prior chemotherapy (P = .027)
and WHO stage V (P = .032) were significantly correlated to OS. The
multivariate analysis confirmed that pretreatment plasma D-dimer
level > 0.5 μg/mL (HR: 3.87, 95% CI: 1.88-7.98; P < .001), prior che-
motherapy (HR: 9.71, 95% CI: 3.27-28.83; P < .001) and WHO stage
V (HR: 3.13, 95% CI: 1.41-6.96; P = .005), were independent predic-
tors of OS.
No significant difference in response rate (76% vs 83%, P = .73),
PFS (HR: 0.73, 95% CI: 0.40-1.33; P = .37) and OS (HR: 0.83, 95% CI:
0.46-1.50; P = .64) was identified between dogs with intermediate to
high-grade NHL treated with F14512 or etoposide phosphate.
4 | DISCUSSION
The results of this prospective study a provide strong evidence that
elevation of pretreatment plasma D-dimer level is associated with
worse outcome in dogs with intermediate to high-grade NHL. In the
present study, pretreatment D-dimer level >0.5 μg/mL was an inde-
pendent predictor for a shorter PFS and OS.
The relationship between D-dimer level and tumours has been
the subject of recent attention. The exact mechanisms underlying the
associated between the D-dimer levels and cancer survival remains to
be elucidated. A probable explanation may be related with the activa-
tion of the coagulation-fibrinolysis system by the cancer cells.38-40
The expression of tissue factors produced by the cancer cells, the
F IGURE 1 Kaplan-Meier survival curves of progression-free
survival, A and overall survival, B, in dogs with high (>0.5 μg/mL,
n = 21) or low (≤0.5 μg/mL, n = 27) pretreatment D-dimer level. Log-
rank P values are shown
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activation of thrombin in tumour microenvironment and the secretion
of proinflammatory factors result in activation of coagulation and
plasminogen activators.39-42 This abnormal activation of coagulation-
fibrinolysis system eventually promotes tumour growth, tumour inva-
sion and angiogenesis.39 Elevated D-dimer level may reflect this
abnormal coagulation-fibrinolysis activation and thereby elevated D-
dimer is associated with worse outcome in cancer patients.
For the purpose of comparison, we compared dogs with a low
(≤0.5 μg/mL) or high (>0.5 μg/mL) pretreatment plasma D-dimer level
based on the published data of D-dimer reference range in clinically
healthy dogs. In the present study, 44% (21/48) of dogs with interme-
diate to high-grade NHL had pretreatment plasma D-dimer level
above 0.5 μg/mL. No significant correlations were found between
pretreatment plasma D-dimer level and clinical features including sex,
age, WHO tumour stage and substage, immunophenotype and treat-
ment response. However, in humans malignant haematopoietic
tumours, high pretreatment plasma D-dimer level correlates with
adverse clinical profiles such as Ann-Arbor stage of III-IV, presence of
b clinical signs, a worse Eastern Cooperative Oncology Group (ECOG)
Performance Status, International Prognostic Index (IPI) score of inter-
mediate and high risk and extra-nodal sites ≥2.56 The small number of
dogs included in the present study might explain the absence of sig-
nificant correlation identified between pretreatment plasma D-dimer
level and the clinical features in dogs and further studies are
warranted to confirm these findings.
Based on a Cox proportional hazard model, our results revealed
that high pretreatment plasma D-dimer level (>0.5 μg/mL) was a sig-
nificant prognostic indicator on PFS and OS in dogs with intermediate
to high-grade NHL and it was found to be an independent determi-
nant of prognosis on multivariate analysis. Other previously described
prognostic indicators on OS in dogs with lymphoma were also identi-
fied in our study, including prior chemotherapy and WHO stage V
lymphoma. However, T-cell immunophenotype and WHO clinical sub-
stage b were not identified as a significant prognostic indicator. These
results might be explained by the small number of dogs included. In
the present study, pretreatment sTK1 activity was also evaluated. A
low correlation was found between pretreatment plasma D-dimer
level and sTK1 activity and pretreatment sTK1 activity was not corre-
lated with PFS and OS. Our results suggest that sTK1 activity may not
be used as a specific prognostic factor in dogs with intermediate to
high-grade NHL.
There are some limitations concerning the present study. First,
the prognostic value of pretreatment plasma D-dimer level was evalu-
ated in a randomized double-blind study, assessing two innovative
anti-neoplastic drugs (F14512 and etoposide phosphate). Pre-
treatment D-dimer level was not a determinative factor for treatment
planning or treatment group assignment. Treatments received were
balanced between the groups of dogs with pretreatment plasma D-
dimer level >0.5 and ≤0.5 μg/mL. There was no difference in response
rate, PFS or OS between dogs with intermediate to high-grade NHL
TABLE 3 Univariate and multivariate analysis of prognostic factors for progression-free survival
Variable
Univariate analysis Multivariate analysis
HR (95% CI) P value FDR adjusted P value HR (95% CI) P value
WHO clinical stage (V vs II + III + IV) 2.75 (1.27-5.95) 0.011 0.066
D-dimer level (> 0.5 vs ≤0.5 μg/mL) 2.22 (1.18–4.19) 0.014 0.042 3.21 (1.57–6.56) .001
Prior chemotherapy (yes vs no) 2.71 (1.16-6.34) 0.021 0.042 5.06 (1.92-13.37) .001
Immunophenotype (T vs B) 2.20 (0.93-5.19) 0.07 0.1
Treatment group (F14512 vs Etoposide phosphate) 0.73 (0.40-1.33) 0.31 0.37
WHO clinical substage (b vs a) 1.27 (0.71-2.26) 0.42 0.42
Abbreviations: FDR, false discovery rate; WHO, World Health Organization.
TABLE 4 Univariate and multivariate analysis of prognostic factors for overall survival
Variable
Univariate analysis Multivariate analysis
HR (95% CI) P value FDR adjusted P value HR (95% CI) P value
D-dimer level (>0.5 vs ≤0.5 μg/mL) 2.53 (1.34-4.78) 0.004 0.024 3.87 (1.88–7.98) <.001
Prior chemotherapy (yes vs no) 3.33 (1.35-8.18) 0.009 0.027 9.71 (3.27-28.83) <.001
WHO clinical stage (V vs II + III + IV) 2.51 (1.19-5.32) 0.016 0.032 3.13 (1.41-6.96) .005
WHO clinical substage (b vs a) 1.43 (0.78-2.61) 0.24 0.36
Treatment group (F14512 vs Etoposide phosphate) 0.83 (0.46-1.50) 0.53 0.64
Immunophenotype (T vs B) 1.28 (0.56-2.92) 0.56 0.56
Abbreviations: FDR, false discovery rate; WHO, World Health Organization.
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treated with F14512 or etoposide phosphate. The results of the pre-
sent study would not have been expected to be significantly affected
by the treatment received. However, a prospective study is warranted
to confirm the predictive value of pretreatment plasma D-dimer level
in dogs with intermediate to high-grade NHL treated with a standard-
ized CHOP-based chemotherapy protocol. Another limitation of the
study is that D-dimer level was measured only once, prior to treat-
ment initiation. Future longitudinal studies with serial measurements
of D-dimer levels would be necessary to evaluate the correlation with
treatment response and disease progression. In addition, elevated D-
dimer levels in human patients with malignant solid tumours were
associated with a hypercoagulable state and increased risk of venous
thromboembolism (VTE).57,58 No dogs in our study experienced symp-
tomatic VTE, indicating that VTE might not be the reason for poor sur-
vival reported in dogs with higher levels of D-dimer. However,
asymptomatic VTE influencing the disease course and prognosis can-
not be excluded. In addition, post-mortem examinations were not rou-
tinely performed, and vascular embolism may have been missed in
some dogs, particularly in dogs with high pretreatment plasma D-
dimer levels.
In conclusion, we herein identified high pretreatment plasma D-
dimer level as a potential marker to predict survival in dogs with inter-
mediate to high-grade NHL. These findings require further validation
in dogs treated with a standardized CHOP-based chemotherapy pro-
tocol and employing a prospective study design.
ACKNOWLEDGEMENTS
We are grateful to the pet owners for participating in this study. We
thank S. Bavcar, M. Longo and H. McDonald for helpful assistance,
comments and discussions. This research was supported by a grant
from BPI-France, through the CANINCA project, a collaborative
research programme with OCR (Oncovet-Clinical-Research), Pierre
Fabre Research Institute and CNRS – UMR 5089.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ETHICS STATEMENT
Ethical approval was obtained from the OCR Ethical Committee
before study initiation.
DATA AVAILABILITY STATEMENT
All data associated with this study are available in the main text or the
supplementary materials (Supporting Information Table S1).
ORCID
Pierre Boyé https://orcid.org/0000-0003-2954-2842
REFERENCES
1. Ponce F, Marchal T, Magnol JP, et al. A morphological study of 608
cases of canine malignant lymphoma in France with a focus on com-
parative similarities between canine and human lymphoma morphol-
ogy. Vet Pathol. 2010;47(3):414-433.
2. Seelig DM, Avery AC, Ehrhart EJ, Linden MA. The comparative diag-
nostic features of canine and human lymphoma. Vet Sci. 2016;3(2):11.
3. Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative
model for human non-Hodgkin lymphoma: recent progress and appli-
cations. Vet Immunol Immunopathol. 2014;159(3–4):192-201.
4. Teske E, Van Heerde P, Rutteman GR, Kurzman ID, Moore PF,
MacEwen EG. Prognostic factors for treatment of malignant lym-
phoma in dogs. J Am Vet Med Assoc. 1994;205(12):1722-1728.
5. Marconato L, Polton GA, Sabattini S, et al. Conformity and controver-
sies in the diagnosis, staging and follow-up evaluation of canine nodal
lymphoma: a systematic review of the last 15 years of published liter-
ature. Vet Comp Oncol. 2017;15(3):1029-1040.
6. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE. Evalua-
tion of prognostic factors and sequential combination chemotherapy
with doxorubicin for canine lymphoma. J Vet Intern Med. 1993;7(5):
289-295.
7. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A ret-
rospective study of the incidence and prognostic factors of multi-
centric lymphoma in dogs (1998-2000). J Vet Med A Physiol Pathol
Clin Med. 2002;49(8):419-424.
8. Simon D, Moreno SN, Hirschberger J, et al. Efficacy of a continuous,
multiagent chemotherapeutic protocol versus a short-term single-
agent protocol in dogs with lymphoma. J Am Vet Med Assoc. 2008;
232(6):879-885.
9. Beaver LM, Strottner G, Klein MK. Response rate after administration
of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma:
41 cases (2006-2008). J Am Vet Med Assoc. 2010;237(9):1052-1055.
10. Rebhun RB, Kent MS, Borrofka SA, Frazier S, Skorupski K,
Rodriguez CO. CHOP chemotherapy for the treatment of canine mul-
ticentric T-cell lymphoma. Vet Comp Oncol. 2011;9(1):38-44.
11. Marconato L, Stefanello D, Valenti P, et al. Predictors of long-term
survival in dogs with high-grade multicentric lymphoma. J Am Vet
Med Assoc. 2011;238(4):480-485.
12. Williams MJ, Avery AC, Lana SE, Hillers KR, Bachand AM, Avery PR.
Canine lymphoproliferative disease characterized by lymphocytosis:
immunophenotypic markers of prognosis. J Vet Intern Med. 2008;22
(3):596-601.
13. Flood-Knapik KE, Durham AC, Gregor TP, Sánchez MD, Durney ME,
Sorenmo KU. Clinical, histopathological and immunohistochemical
characterization of canine indolent lymphoma. Vet Comp Oncol. 2013;
11(4):272-286.
14. Valli VE, Kass PH, San Myint M, Scott F. Canine lymphomas: associa-
tion of classification type, disease stage, tumor subtype, mitotic rate,
and treatment with survival. Vet Pathol. 2013;50(5):738-748.
15. Ponce F, Magnol JP, Ledieu D, et al. Prognostic significance of mor-
phological subtypes in canine malignant lymphomas during chemo-
therapy. Vet J. 2004;167(2):158-166.
16. Williams LE, Rassnick KM, Power HT, et al. CCNU in the treatment of
canine epitheliotropic lymphoma. J Vet Intern Med. 2006;20(1):
136-143.
17. Rassnick KM, Moore AS, Collister KE, et al. Efficacy of combination
chemotherapy for treatment of gastrointestinal lymphoma in dogs. J
Vet Intern Med. 2009;23(2):317-322.
18. Keller SM, Vernau W, Hodges J, et al. Hepatosplenic and
hepatocytotropic T-cell lymphoma: two distinct types of T-cell lym-
phoma in dogs. Vet Pathol. 2013;50(2):281-290.
19. Mealey KL, Bentjen SA, Gay JM, Hosick HL. Dexamethasone treat-
ment of a canine, but not human, tumour cell line increases
chemoresistance independent of P-glycoprotein and multidrug resis-
tance-related protein expression. Vet Comp Oncol. 2003;1(2):67-75.
20. Vail DM, Kravis LD, Kisseberth WC, Ogilvie GK, Volk LM. Application
of rapid CD3 immunophenotype analysis and argyrophilic nucleolar
organizer region (AgNOR) frequency to fine needle aspirate speci-
mens from dogs with lymphoma. Vet Clin Pathol. 1997;26(2):66-69.
BOYÉ ET AL. 7
21. Renwick MG, Argyle DJ, Long S, Nixon C, Gault EA, Nasir L. Telome-
rase activity and telomerase reverse transcriptase catalytic subunit
expression in canine lymphoma: correlation with Ki67 immunoreac-
tivity. Vet Comp Oncol. 2006;4(3):141-150.
22. Zanatta R, Abate O, D'Angelo A, Miniscalco B, Mannelli A. Diagnostic
and prognostic value of serum lactate dehydrogenase (LDH) and LDH
isoenzymes in canine lymphoma. Vet Res Commun. 2003;27(suppl 1):
449-452.
23. Marconato L, Crispino G, Finotello R, Mazzotti S, Zini E. Clinical rele-
vance of serial determinations of lactate dehydrogenase activity used
to predict recurrence in dogs with lymphoma. J Am Vet Med Assoc.
2010;236(9):969-974.
24. Nielsen L, Toft N, Eckersall PD, Mellor DJ, Morris JS. Serum C-reac-
tive protein concentration as an indicator of remission status in dogs
with multicentric lymphoma. J Vet Intern Med. 2007;21(6):1231-
1236.
25. Fontaine SJ, McCulloch E, Eckersall PD, Haining H, Patterson
Kane JC, Morris JS. Evaluation of the modified Glasgow prognostic
score to predict outcome in dogs with newly diagnosed lymphoma.
Vet Comp Oncol. 2017;15(4):1513-1526.
26. Von Euler H, Einarsson R, Olsson U, Lagerstedt AS, Eriksson S. Serum
thymidine kinase activity in dogs with malignant lymphoma: a potent
marker for prognosis and monitoring the disease. J Vet Intern Med.
2004;18(5):696-702.
27. De Buyzere M, Philippé J, Duprez D, Baele G, Clement DL. Coagula-
tion system activation and increase of D-dimer levels in peripheral
arterial occlusive disease. Am J Hematol. 1993;43(2):91-94.
28. Batschauer APB, Figueiredo CP, Bueno EC, et al. D-dimer as a possi-
ble prognostic marker of operable hormone receptor-negative breast
cancer. Ann Oncol. 2010;21(6):1267-1272.
29. Yamamoto M, Yoshinaga K, Matsuyama A, et al. Plasma D-dimer level
as a mortality predictor in patients with advanced or recurrent colo-
rectal cancer. OCL. 2012;83(1):10-15.
30. Blackwell K, Hurwitz H, Liebérman G, et al. Circulating D-dimer levels
are better predictors of overall survival and disease progression than
carcinoembryonic antigen levels in patients with metastatic colorectal
carcinoma. Cancer. 2004;101(1):77-82.
31. Zhang PP, Sun JW, Wang XY, Liu XM, Li K. Preoperative plasma D-
dimer levels predict survival in patients with operable non-small cell
lung cancer independently of venous thromboembolism. Eur J Surg
Oncol. 2013;39(9):951-956.
32. Fukumoto K, Taniguchi T, Usami N, et al. Preoperative plasma D-
dimer level is an independent prognostic factor in patients with
completely resected non-small cell lung cancer. Surg Today. 2015;45
(1):63-67.
33. Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are
associated with shorter overall survival in patients with small cell lung
cancer. J Int Med Res. 2019;47(1):215-224.
34. Liu L, Zhang X, Yan B, et al. Elevated plasma D-dimer levels correlate
with long term survival of gastric cancer patients. PLoS ONE. 2014;9
(3):e90547.
35. Go SI, Lee MJ, Lee WS, et al. D-dimer can serve as a prognostic and
predictive biomarker for metastatic gastric cancer treated by chemo-
therapy. Medicine (Baltimore). 2015;94(30):e951.
36. Nakamura K, Nakayama K, Ishikawa M, et al. High pre-treatment
plasma D-dimer level as a potential prognostic biomarker for cervical
carcinoma. Anticancer Res. 2016;36(6):2933-2938.
37. Liu B, Li B, Zhou P, et al. Prognostic value of pretreatment plasma D-
dimer levels in patients with diffuse large B cell lymphoma (DLBCL).
Clin Chim Acta. 2018;482:191-198.
38. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer
and thrombosis: from molecular mechanisms to clinical presentations.
J Thromb Haemost. 2007;5(suppl 1):246-254.
39. Ruf W, Yokota N, Schaffner F. Tissue factor in cancer progression
and angiogenesis. Thromb Res. 2010;125(suppl 2):S36-S38.
40. Bick RL. Coagulation abnormalities in malignancy: a review. Semin
Thromb Hemost. 1992;18(4):353-372.
41. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in can-
cer. J Clin Oncol. 2009;27(29):4834-4838.
42. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts
and future prospects. Blood. 2009;113(13):2878-2887.
43. Kristensen AT, Wiinberg B, Jessen LR, Andreasen E, Jensen AL. Evalu-
ation of human recombinant tissue factor-activated
thromboelastography in 49 dogs with neoplasia. J Vet Intern Med.
2008;22(1):140-147.
44. Andreasen EB, Tranholm M, Wiinberg B, Markussen B,
Kristensen AT. Haemostatic alterations in a group of canine cancer
patients are associated with cancer type and disease progression.
Acta Vet Scand. 2012;54:3.
45. Font C, de la Fuente C, Pumarola M, et al. Canine intracranial menin-
giomas: Immunohistochemical evaluation of tissue factor,
fibrin/fibrinogen and D-dimers. Vet J. 2015;206(3):426-428.
46. Serres F, Tierny D, Hidalgo A, Haelewyn C, Marescaux L. Assessment
and prognostic implication of D-dimer value in dogs with miscella-
neous tumors: a prospective study of 149 dogs. In: Proceedings of
the 2011 Annual Congress of the European Society of Veterinary
Oncology (ESVONC), Glasgow, UK, 24-26th March, 2011.
47. Boyé P, Floch F, Serres F, et al. Randomized, double-blind trial of
F14512, a polyamine-vectorized anticancer drug, compared with
etoposide phosphate, in dogs with naturally occurring lymphoma.
Oncotarget. 2020;11:671-686.
48. Marconato L, Martini V, Aresu L, et al. Assessment of bone marrow
infiltration diagnosed by flow cytometry in canine large B cell lym-
phoma: prognostic significance and proposal of a cut-off value. Vet J.
2013;197(3):776-781.
49. Fournel-Fleury C, Magnol JP, Bricaire P, et al. Cytohistological and
immunological classification of canine malignant lymphomas: compar-
ison with human non-Hodgkin's lymphomas. J Comp Pathol. 1997;
117(1):35-59.
50. Tierny D, Serres F, Segaoula Z, et al. Phase I clinical pharmacology
study of F14512, a new polyamine-vectorized anticancer drug, in nat-
urally occurring canine lymphoma. Clin Cancer Res. 2015;21(23):
5314-5323.
51. Dewhurst E, Cue S, Crawford E, Papasouliotis K. A retrospective
study of canine D-dimer concentrations measured using an
immunometric « Point-of-Care » test. J Small Anim Pract. 2008;49(7):
344-348.
52. Boyé P, Floch F, Serres F, et al. Evaluation of serum thymidine kinase
1 activity as a biomarker for treatment effectiveness and prediction
of relapse in dogs with non-Hodgkin lymphoma. J Vet Intern Med.
2019;33(4):1728-1739.
53. Boyé P, Serres F, Marescaux L, et al. Dose escalation study to evalu-
ate safety, tolerability and efficacy of intravenous etoposide phos-
phate administration in 27 dogs with multicentric lymphoma. PLoS
ONE. 2017;12(5):e0177486.
54. Vail DM, Michels GM, Khanna C, Selting KA, London CA, Veterinary
Cooperative Oncology Group. Response evaluation criteria for
peripheral nodal lymphoma in dogs (v1.0) – a veterinary cooperative
oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;
8(1):28-37.
55. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a prac-
tical and powerful approach to multiple testing. J R Stat Soc B Met-
hodol. 1995;57(1):289-300.
56. Bi X, Wang L, Zhang W, et al. High pretreatment D-dimer levels cor-
relate with adverse clinical features and predict poor survival in
patients with natural killer/T-cell lymphoma. PLoS ONE. 2016;11(3):
e0152842.
57. Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemother-
apy might predict venous thromboembolism. Blood Coagul Fibrinolysis.
2009;20(3):170-175.
8 BOYÉ ET AL.
58. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin frag-
ment 1 + 2 predict venous thromboembolism in patients with cancer:
results from the Vienna cancer and thrombosis study. J Clin Oncol.
2009;27(25):4124-4129.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Boyé P, Serres F, Floch F, Fournel-
Fleury C, Tierny D. Prognostic value of pretreatment plasma
D-dimer level in dogs with intermediate to high-grade non-
Hodgkin lymphoma. Vet Comp Oncol. 2020;1–9. https://doi.
org/10.1111/vco.12629
BOYÉ ET AL. 9
